Lumexa Imaging (LMRI) vs MaxCyte (MXCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lumexa Imaging is the larger company by market cap ($992.5 million vs $105.3 million), about 9.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LMRI | MXCT |
|---|---|---|
| Share price | $10.33 | $1.02 |
| Market cap | $992.45M | $105.27M |
| 1-day change | -2.46% | -1.92% |
| YTD return | -44.16% | -34.19% |
| 1-year return | — | -40.00% |
| 5-year return | — | -90.75% |
| Forward P/E | 11.61 | — |
| EPS (TTM) | $-0.37 | $-0.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.45 | $1.87 |
| 52-week low | $6.45 | $0.643 |
| Distance from 52-week high | -46.89% | -45.31% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +71.06% | +302.94% |
| Average volume | 430.76K | 668.82K |
| Shares outstanding | 96.07M | 103.21M |
| Employees | 5,000 | 91 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Lumexa Imaging is about 9.4 times larger than MaxCyte by market value ($992.45M vs $105.27M).
About Lumexa Imaging
LMRI stock →Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States.
Health Care · Medical Specialities · 5,000 employees
About MaxCyte
MXCT stock →MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 91 employees
LMRI vs MXCT FAQ
Which is bigger, Lumexa Imaging or MaxCyte?
Lumexa Imaging (LMRI) is larger, with a market capitalization of $992.45M compared with $105.27M for MaxCyte (MXCT).
Are Lumexa Imaging and MaxCyte in the same industry?
Both are in the Health Care sector, but in different industries: Medical Specialities for Lumexa Imaging and Biotechnology: Commercial Physical & Biological Resarch for MaxCyte.